All In Biotech

NDA 021928 · Pf Prism Cv

Chantix

Varenicline Tartrate · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jun 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

May 10, 2006

Approved uses

15

Original approval plus efficacy supplements

Registered trials

336

68 Phase 3, 23 recruiting

FAERS reports

76,596

31,194 serious, 1,581 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 23, 2026.

CHANTIX is indicated for use as an aid to smoking-cessation treatment. CHANTIX is a nicotinic receptor partial agonist indicated for use as an aid to smoking-cessation treatment. ( 1 and 2.1 )

Mechanism: Varenicline binds with high affinity and selectivity at α4β2 neuronal nicotinic acetylcholine receptors. The efficacy of CHANTIX in smoking cessation is believed to be the result of varenicline's activity at α4β2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these receptors. Electrophysiology studies in vitro and neurochemical studies in vivo have shown that varenicline binds to α4β2 neuronal nicotinic acetylcholine receptors and stimulates receptor-mediated activity, but at a significantly lower level than...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • CHANTIX · VARENICLINE TARTRATE EQ 0.5MG BASE · TABLET, ORAL · Prescription · TE AB
  • CHANTIX · VARENICLINE TARTRATE EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Varenicline" as an intervention, any sponsor and status, largest first.

All 336 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea13,951
  • depression8,329
  • abnormal dreams7,633
  • anxiety5,827
  • drug ineffective5,559
  • insomnia5,430
  • vomiting4,244
  • headache4,035
  • suicidal ideation4,000
  • malaise3,952
  • feeling abnormal3,940
  • nightmare3,151

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2006213
20073,076
20084,745
20091,550
201029,906
20116,391
20126,935
20133,307
20143,575
20152,251
20162,447
20172,396
20182,274
20192,535
20201,792
20211,180
20221,027
2023312
2024218
2025249
2026217

Recalls

7 FDA enforcement reports for this application.

  • Aug 13, 2021 · Class II · Ongoing

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

  • Aug 13, 2021 · Class II · Ongoing

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

  • Jun 9, 2021 · Class II · Ongoing

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

  • Jun 9, 2021 · Class II · Ongoing

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit

  • Jun 9, 2021 · Class II · Ongoing

    CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Chantix (Varenicline Tartrate)

2024 spending

$10K

Beneficiaries

14

25 claims

Per beneficiary

$706

$8.13 per unit

View as table
YearSpending
2020$298,651,751
2021$153,238,580
2022$750,396
2023$88,399
2024$9,885

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 604 on PubMed

Sponsor: Pf Prism Cv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.